PortalPublikationenThe impact of vitrectomy on outcomes achieved with 0.19 mg f...

The impact of vitrectomy on outcomes achieved with 0.19 mg fluocinolone acetonide implant in patients with diabetic macular edema

Standard

The impact of vitrectomy on outcomes achieved with 0.19 mg fluocinolone acetonide implant in patients with diabetic macular edema. / Augustin, Albert J; Bopp, Silvia; Fechner, Martin; Holz, Frank G; Sandner, Dirk; Winkgen, Andrea-M; Khoramnia, Ramin; Neuhann, Thomas; Warscher, Markus; Spitzer, Martin S; Sekundo, Walter; Seitz, Berthold; Duncker, Tobias; Ksinsik, Christian; Höh, Helmut.

in: EUR J OPHTHALMOL, Jahrgang 32, Nr. 2, 03.2022, S. 1101-1108.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Augustin, AJ, Bopp, S, Fechner, M, Holz, FG, Sandner, D, Winkgen, A-M, Khoramnia, R, Neuhann, T, Warscher, M, Spitzer, MS, Sekundo, W, Seitz, B, Duncker, T, Ksinsik, C & Höh, H 2022, 'The impact of vitrectomy on outcomes achieved with 0.19 mg fluocinolone acetonide implant in patients with diabetic macular edema', EUR J OPHTHALMOL, Jg. 32, Nr. 2, S. 1101-1108. https://doi.org/10.1177/11206721211014728

APA

Augustin, A. J., Bopp, S., Fechner, M., Holz, F. G., Sandner, D., Winkgen, A-M., Khoramnia, R., Neuhann, T., Warscher, M., Spitzer, M. S., Sekundo, W., Seitz, B., Duncker, T., Ksinsik, C., & Höh, H. (2022). The impact of vitrectomy on outcomes achieved with 0.19 mg fluocinolone acetonide implant in patients with diabetic macular edema. EUR J OPHTHALMOL, 32(2), 1101-1108. https://doi.org/10.1177/11206721211014728

Vancouver

Augustin AJ, Bopp S, Fechner M, Holz FG, Sandner D, Winkgen A-M et al. The impact of vitrectomy on outcomes achieved with 0.19 mg fluocinolone acetonide implant in patients with diabetic macular edema. EUR J OPHTHALMOL. 2022 Mär;32(2):1101-1108. https://doi.org/10.1177/11206721211014728

Bibtex

@article{ac6387c50d1c499dbabb16dfeb50bf6d,
title = "The impact of vitrectomy on outcomes achieved with 0.19 mg fluocinolone acetonide implant in patients with diabetic macular edema",
abstract = "BACKGROUND: There is a lack of consensus on the use of intravitreal corticosteroid therapies in patients with diabetic macular edema (DME) and prior vitrectomized eyes in clinical practice.METHODS: Retro-IDEAL was a 3-year retrospective, multicenter study in patients with chronic DME (i.e. DME that persists or recurs despite treatment) treated with ILUVIEN{\textregistered} (0.2 µg daily fluocinolone acetonide intravitreal implant), who had suboptimal outcomes with first-line vascular endothelial growth-factor inhibitors and other DME therapies.RESULTS: A total of 81 eyes (63 patients) were included of which 39 eyes had undergone prior vitrectomy (PV group) while 42 eyes had not undergone prior vitrectomy (NPV). Baseline characteristics were balanced; however, more patients had proliferative diabetic retinopathy in the PV group vs. the NPV group (21.62% vs 9.38%, respectively). Over 36 months, mean visual acuity (VA) increased in both groups with a tendency for more ETDRS letters being gained in the NPV group (+5.33) vs. the PV group (+2.42). By month 36, central retinal thickness was reduced to ⩽300 µm in two-thirds of the eyes in both groups and the mean change from baseline in intraocular pressure was similar in both groups (+0.50 mmHg -0.75 mmHg; NPV and PV group).CONCLUSIONS: These long-term data suggest that the 0.2 μg/day FAc implant is effective in both vitrectomized and non-vitrectomized patients, with a manageable safety profile, and improved VA and reduced supplemental therapies for patients with a suboptimal response to first-line DME therapies. Clinicians may consider utilizing the FAc implant earlier in the DME disease process.",
author = "Augustin, {Albert J} and Silvia Bopp and Martin Fechner and Holz, {Frank G} and Dirk Sandner and Andrea-M Winkgen and Ramin Khoramnia and Thomas Neuhann and Markus Warscher and Spitzer, {Martin S} and Walter Sekundo and Berthold Seitz and Tobias Duncker and Christian Ksinsik and Helmut H{\"o}h",
year = "2022",
month = mar,
doi = "10.1177/11206721211014728",
language = "English",
volume = "32",
pages = "1101--1108",
journal = "EUR J OPHTHALMOL",
issn = "1120-6721",
publisher = "Wichtig Publishing Srl",
number = "2",

}

RIS

TY - JOUR

T1 - The impact of vitrectomy on outcomes achieved with 0.19 mg fluocinolone acetonide implant in patients with diabetic macular edema

AU - Augustin, Albert J

AU - Bopp, Silvia

AU - Fechner, Martin

AU - Holz, Frank G

AU - Sandner, Dirk

AU - Winkgen, Andrea-M

AU - Khoramnia, Ramin

AU - Neuhann, Thomas

AU - Warscher, Markus

AU - Spitzer, Martin S

AU - Sekundo, Walter

AU - Seitz, Berthold

AU - Duncker, Tobias

AU - Ksinsik, Christian

AU - Höh, Helmut

PY - 2022/3

Y1 - 2022/3

N2 - BACKGROUND: There is a lack of consensus on the use of intravitreal corticosteroid therapies in patients with diabetic macular edema (DME) and prior vitrectomized eyes in clinical practice.METHODS: Retro-IDEAL was a 3-year retrospective, multicenter study in patients with chronic DME (i.e. DME that persists or recurs despite treatment) treated with ILUVIEN® (0.2 µg daily fluocinolone acetonide intravitreal implant), who had suboptimal outcomes with first-line vascular endothelial growth-factor inhibitors and other DME therapies.RESULTS: A total of 81 eyes (63 patients) were included of which 39 eyes had undergone prior vitrectomy (PV group) while 42 eyes had not undergone prior vitrectomy (NPV). Baseline characteristics were balanced; however, more patients had proliferative diabetic retinopathy in the PV group vs. the NPV group (21.62% vs 9.38%, respectively). Over 36 months, mean visual acuity (VA) increased in both groups with a tendency for more ETDRS letters being gained in the NPV group (+5.33) vs. the PV group (+2.42). By month 36, central retinal thickness was reduced to ⩽300 µm in two-thirds of the eyes in both groups and the mean change from baseline in intraocular pressure was similar in both groups (+0.50 mmHg -0.75 mmHg; NPV and PV group).CONCLUSIONS: These long-term data suggest that the 0.2 μg/day FAc implant is effective in both vitrectomized and non-vitrectomized patients, with a manageable safety profile, and improved VA and reduced supplemental therapies for patients with a suboptimal response to first-line DME therapies. Clinicians may consider utilizing the FAc implant earlier in the DME disease process.

AB - BACKGROUND: There is a lack of consensus on the use of intravitreal corticosteroid therapies in patients with diabetic macular edema (DME) and prior vitrectomized eyes in clinical practice.METHODS: Retro-IDEAL was a 3-year retrospective, multicenter study in patients with chronic DME (i.e. DME that persists or recurs despite treatment) treated with ILUVIEN® (0.2 µg daily fluocinolone acetonide intravitreal implant), who had suboptimal outcomes with first-line vascular endothelial growth-factor inhibitors and other DME therapies.RESULTS: A total of 81 eyes (63 patients) were included of which 39 eyes had undergone prior vitrectomy (PV group) while 42 eyes had not undergone prior vitrectomy (NPV). Baseline characteristics were balanced; however, more patients had proliferative diabetic retinopathy in the PV group vs. the NPV group (21.62% vs 9.38%, respectively). Over 36 months, mean visual acuity (VA) increased in both groups with a tendency for more ETDRS letters being gained in the NPV group (+5.33) vs. the PV group (+2.42). By month 36, central retinal thickness was reduced to ⩽300 µm in two-thirds of the eyes in both groups and the mean change from baseline in intraocular pressure was similar in both groups (+0.50 mmHg -0.75 mmHg; NPV and PV group).CONCLUSIONS: These long-term data suggest that the 0.2 μg/day FAc implant is effective in both vitrectomized and non-vitrectomized patients, with a manageable safety profile, and improved VA and reduced supplemental therapies for patients with a suboptimal response to first-line DME therapies. Clinicians may consider utilizing the FAc implant earlier in the DME disease process.

U2 - 10.1177/11206721211014728

DO - 10.1177/11206721211014728

M3 - SCORING: Journal article

C2 - 33947233

VL - 32

SP - 1101

EP - 1108

JO - EUR J OPHTHALMOL

JF - EUR J OPHTHALMOL

SN - 1120-6721

IS - 2

ER -